Omada survey finds only 18% of respondents who discontinued GLP-1s achieved their weight loss goals
Omada Health has released findings from an attitudinal survey of 1,000 non-Omada members to better understand the needs of consumers...
top of page
Browse by category
Search
GLP-1s: Second year cost of care is $4,200 higher for patients with obesity
Individuals without diabetes who newly started glucagon-like peptide-1 (GLP-1) agonist drugs for obesity experienced an average of $4,206...
GLP-1 use doubles as bariatric surgery declines by 25%
A study by researchers at Brigham and Women's Hospital, in collaboration with researchers at Harvard TH Chan School of Public Health and...
Expanding access to weight-loss drugs could save thousands of lives a year
Expanding access to the new generation of weight-loss medications could prevent more than 40,000 deaths a year in the US, according to a...
Popularity of GLP-1s among privately insured patients may worsen disparities
Publicly insured US individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than...
Specialised weight navigation programme increases a patient’s chances of receiving at least one evidence-based weight-management treatment and resulted in more weight loss
Giving high-risk patients access to an obesity specialist through their regular primary care clinic increased their chances of receiving...
Study to analyse the real-world effectiveness of GLP-1 weight-loss drugs and inequities in access to these medications
The Robert Wood Johnson Foundation has awarded a grant to Andrew Stokes, associate professor of global health, Boston University School...
Browse by tag
bottom of page